Cytokinetics, Inc. (CYTK) announced the publication of its Phase II Evidence of Effect clinical study of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis, or ALS.
The results showed that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS that were studied. In addition, measures of muscle endurance appeared to be improved in a dose-related fashion in patients who received CK-2017357. Also, patients who received CK-2017357, and their investigators, perceived a global benefit on treatment.
The company noted that data from the study, which compared single doses of CK-2017357 to placebo, informed the design of subsequent studies conducted by it which have assessed the safety and tolerability of CK-2017357 in other dosing regimens.
For comments and feedback: editorial@rttnews.com